Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)
Cephalalgia · 2025
DOI: 10.1177/03331024251374569 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2025. Verfasst von Yasuhiko Matsumori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists, Dipeptides, Quinazolines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Atogepant is an oral calcitonin gene–related peptide receptor antagonist approved in the US and EU for the preventive treatment of migraine in adults. We evaluated the efficacy, safety, and tolerability of atogepant for the preventive treatment of episodic migraine (EM) in Japanese participants.
Methods
RELEASE was a phase 2/3, multicenter, randomized, double-blind, placebo-controlled study enrolling adult participants with a ≥1-year history of migraine,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan.
- Umenotsuji Clinic, Kochi, Japan.
- Nagaseki Headache Clinic, Yamanashi, Japan.
- Tokyo Headache Clinic, Tokyo, Japan.
- AbbVie, North Chicago, IL, USA.
- AbbVie GK, Tokyo, Japan.
ORCID-Profile: Krisztian Nagy, Gina Ahmadyar
Förderung
- AbbVie
Zitieren
APA
Matsumori, Y., Yamada, H., Nagaseki, Y., Shimizu, K., Nagy, K., Matsuzawa, R., Otani, T., He, M. Y., Guo, H., Ahmadyar, G., & Takeshima, T. (2025). Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. https://doi.org/10.1177/03331024251374569
Vancouver
Matsumori Y, Yamada H, Nagaseki Y, Shimizu K, Nagy K, Matsuzawa R, et al. Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025. doi:10.1177/03331024251374569
BibTeX
@article{Matsumori2025,
author = {Matsumori, Yasuhiko and Yamada, Hiroshi and Nagaseki, Yoshishige and Shimizu, Kazutaka and Nagy, Krisztian and Matsuzawa, Ryotaro and Otani, Tetsuya and He, Molly Yizeng and Guo, Hua and Ahmadyar, Gina and Takeshima, Takao},
title = {Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251374569}
}
EUVIMED